Oct. 3, 2012 New research proves the validity of one of the most promising approaches for combating Alzheimer's disease (AD) with medicines that treat not just some of the symptoms, but actually stop or prevent the disease itself, scientists are reporting.
The study, in the journal ACS Medicinal Chemistry Letters, also identifies a potential new oral drug that the scientists say could lead the way.
Wenhui Hu and colleagues point out that existing drugs for AD provide only "minimal" relief of memory loss and other symptoms, creating an urgent need for new medicines that actually combat the underlying destruction of brain cells. Research suggests that inflammation of nerve cells in the brain is a key part of that process. One medicine, Minozac, is in clinical trials. But Hu says Minozac still has more space to improve its efficacy. So the scientists sifted through compounds with a molecular architecture similar to Minozac in an effort to find more active substances.
The report describes success in doing so. They discovered one compound that appeared especially effective in relieving nerve inflammation and in improving learning and memory in lab mice widely used in AD research. "In general, this study not only proves that countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's disease, but also provides a good lead compound with efficacy comparable to donepezil [an existing AD medicine] for further oral anti-AD drug discovery and development," the report states.
Other social bookmarking and sharing tools:
- Wei Zhou, Guifa Zhong, Xiurong Rao, Hui Xie, Shaogao Zeng, Tianyan Chi, Libo Zou, Donghai Wu, Wenhui Hu. Identification of Aminopyridazine-Derived Antineuroinflammatory Agents Effective in an Alzheimer's Mouse Model. ACS Medicinal Chemistry Letters, 2012; : 120913133048003 DOI: 10.1021/ml3001769
Note: If no author is given, the source is cited instead.